Impact of the Time Interval Between Primary Debulking Surgery and Start of Adjuvant Chemotherapy in Advanced Epithelial Ovarian Cancer

References

• Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–249. doi:10.3322/caac.2166033538338
   PubMed Web of Science ®Google Scholar
• Gourley C, Bookman MA. Evolving concepts in the management of newly diagnosed epithelial ovarian cancer. J Clin Oncol. 2019;37(27):2386–2397. doi:10.1200/JCO.19.0033731403859
   PubMed Web of Science ®Google Scholar
• Armstrong DK, Alvarez RD, Bakkum-Gamez JN, et al. Ovarian cancer, version 2.2020, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2021;19(2):191–226. doi:10.6004/jnccn.2021.000733545690
   PubMed Web of Science ®Google Scholar
• Kuroki L, Guntupalli SR. Treatment of epithelial ovarian cancer. BMJ. 2020;371:m3773. doi:10.1136/bmj.m377333168565
   PubMed Web of Science ®Google Scholar
• Tewari KS, Java JJ, Eskander RN, Monk BJ, Burger RA. Early initiation of chemotherapy following complete resection of advanced ovarian cancer associated with improved survival: NRG Oncology/Gynecologic Oncology Group study. Ann Oncol. 2016;27(1):114–121. doi:10.1093/annonc/mdv50026487588
   PubMed Web of Science ®Google Scholar
• Kohandel M, Sivaloganathan S, Oza A. Mathematical modeling of ovarian cancer treatments: sequencing of surgery and chemotherapy. J Theor Biol. 2006;242(1):62–68. doi:10.1016/j.jtbi.2006.02.00116580022
   PubMed Web of Science ®Google Scholar
• Kang KM, Hong KS, Noh GT, et al. Optimal time of initiating adjuvant chemotherapy after curative surgery in colorectal cancer patients. Ann Coloproctol. 2013;29(4):150–154. doi:10.3393/ac.2013.29.4.15024032115
   PubMedGoogle Scholar
• Lohrisch C, Paltiel C, Gelmon K, et al. Impact on survival of time from definitive surgery to initiation of adjuvant chemotherapy for early-stage breast cancer. J Clin Oncol. 2006;24(30):4888–4894. doi:10.1200/JCO.2005.01.608917015884
   PubMed Web of Science ®Google Scholar
• Gadducci A, Sartori E, Landoni F, et al. Relationship between time interval from primary surgery to the start of taxane- plus platinum-based chemotherapy and clinical outcome of patients with advanced epithelial ovarian cancer: results of a multicenter retrospective Italian study. J Clin Oncol. 2005;23(4):751–758. doi:10.1200/JCO.2005.03.06515613698
   PubMed Web of Science ®Google Scholar
• Aletti GD, Long HJ, Podratz KC, Cliby WA. Is time to chemotherapy a determinant of prognosis in advanced-stage ovarian cancer? Gynecol Oncol. 2007;104(1):212–216. doi:10.1016/j.ygyno.2006.07.04517023033
   PubMed Web of Science ®Google Scholar
• Zeng XT, Li S, Gong K, et al. [Evidence-based evaluation of recent clinical practice guidelines for the diagnosis and treatment of benign prostatic hyperplasia]. Zhonghua Yi Xue Za Zhi. 2017;97(22):1683–1687. doi:10.3760/cma.j.issn.0376-2491.2017.22.002. Chinese.28606274
   PubMedGoogle Scholar
• Rocher G, Gaillard T, Uzan C, et al. Does time-to-chemotherapy after primary complete macroscopic cytoreductive surgery influence prognosis for patients with epithelial ovarian cancer? A study of the FRANCOGYN group. J Clin Med. 2021;10(5):1058. doi:10.3390/jcm1005105833806443
   PubMed Web of Science ®Google Scholar
• Bookman MA, Okamoto A, Stuart G, et al. Harmonising clinical trials within the Gynecologic Cancer InterGroup: consensus and unmet needs from the Fifth Ovarian Cancer Consensus Conference. Ann Oncol. 2017;28(suppl_8):viii30–viii35. doi:10.1093/annonc/mdx44929232472
   PubMed Web of Science ®Google Scholar
• Lydiksen L, Jensen-Fangel S, Blaakaer J. Is it possible to define an optimal time for chemotherapy after surgery for ovarian cancer? Gynecol Oncol. 2014;133(3):454–459. doi:10.1016/j.ygyno.2014.04.00424726613
   PubMed Web of Science ®Google Scholar
• Wright J, Doan T, McBride R, Jacobson J, Hershman D. Variability in chemotherapy delivery for elderly women with advanced stage ovarian cancer and its impact on survival. Br J Cancer. 2008;98(7):1197–1203. doi:10.1038/sj.bjc.660429818349836
   PubMed Web of Science ®Google Scholar
• Timmermans M, van der Aa MA, Lalisang RI, et al. Interval between debulking surgery and adjuvant chemotherapy is associated with overall survival in patients with advanced ovarian cancer. Gynecol Oncol. 2018;150(3):446–450. doi:10.1016/j.ygyno.2018.07.00430001834
   PubMed Web of Science ®Google Scholar
• Seagle BL, Butler SK, Strohl AE, Nieves-Neira W, Shahabi S. Chemotherapy delay after primary debulking surgery for ovarian cancer. Gynecol Oncol. 2017;144(2):260–265. doi:10.1016/j.ygyno.2016.11.02227908531
   PubMed Web of Science ®Google Scholar
• Selvin S. Two issues concerning the analysis of grouped data. Eur J Epidemiol. 1987;3(3):284–287. doi:10.1007/BF001497373653356
   PubMed Web of Science ®Google Scholar
• Altman DG. Categorizing continuous variables. Wiley StatsRef: Statistics Reference Online. 2014.
   Google Scholar
• Manning-Geist BL, Hicks-Courant K, Gockley AA, et al. Moving beyond “complete surgical resection” and “optimal”: is low-volume residual disease another option for primary debulking surgery? Gynecol Oncol. 2018;150(2):233–238. doi:10.1016/j.ygyno.2018.06.01529933927
   PubMed Web of Science ®Google Scholar
• Hofstetter G, Concin N, Braicu I, et al. The time interval from surgery to start of chemotherapy significantly impacts prognosis in patients with advanced serous ovarian carcinoma - analysis of patient data in the prospective OVCAD study. Gynecol Oncol. 2013;131(1):15–20. doi:10.1016/j.ygyno.2013.07.08623877013
   PubMed Web of Science ®Google Scholar
• Wright JD, Herzog TJ, Neugut AI, et al. Effect of radical cytoreductive surgery on omission and delay of chemotherapy for advanced-stage ovarian cancer. Obstet Gynecol. 2012;120(4):871–881. doi:10.1097/AOG.0b013e31826981de22996105
   PubMed Web of Science ®Google Scholar
• Fotopoulou C, Jones BP, Savvatis K, et al. Maximal effort cytoreductive surgery for disseminated ovarian cancer in a UK setting: challenges and possibilities. Arch Gynecol Obstet. 2016;294(3):607–614. doi:10.1007/s00404-016-4080-327040418
   PubMed Web of Science ®Google Scholar
• Flynn PM, Paul J, Cruickshank DJ. Does the interval from primary surgery to chemotherapy influence progression-free survival in ovarian cancer? Gynecol Oncol. 2002;86(3):354–357. doi:10.1006/gyno.2002.675012217760
   PubMed Web of Science ®Google Scholar
• Usón PLJ, Bugano DD, França MS, et al. Does time-to-chemotherapy impact the outcomes of resected ovarian cancer? Meta-analysis of randomized and observational data. Int J Gynecol Cancer. 2017;27(2):274–280. doi:10.1097/igc.000000000000092328114235
   PubMed Web of Science ®Google Scholar
• Mahner S, Eulenburg C, Staehle A, et al. Prognostic impact of the time interval between surgery and chemotherapy in advanced ovarian cancer: analysis of prospective randomised phase III trials. Eur J Cancer. 2013;49(1):142–149. doi:10.1016/j.ejca.2012.07.02322921185
   PubMed Web of Science ®Google Scholar
• Fisher B, Gunduz N, Saffer EA. Influence of the interval between primary tumor removal and chemotherapy on kinetics and growth of metastases. Cancer Res. 1983;43(4):1488–1492.6831397
   PubMed Web of Science ®Google Scholar
• Schiffenbauer YS, Abramovitch R, Meir G, et al. Loss of ovarian function promotes angiogenesis in human ovarian carcinoma. Proc Natl Acad Sci U S A. 1997;94(24):13203–13208. doi:10.1073/pnas.94.24.132039371824
   PubMed Web of Science ®Google Scholar
• Oza AM, Cook AD, Pfisterer J, et al. ICON7 trial investigators. Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a Phase 3 randomised trial. Lancet Oncol. 2015;16(8):928–936. doi:10.1016/S1470-2045(15)00086-826115797
   PubMed Web of Science ®Google Scholar
• Burger RA, Brady MF, Bookman MA, et al. Gynecologic Oncology Group. Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med. 2011;365(26):2473–2483. doi:10.1056/NEJMoa110439022204724
   PubMed Web of Science ®Google Scholar